Obesity and Prostate Cancer: A Role for Adipokines

European Urology

Volumn 52, Issue 1, 2007, Pages 46-53

  Mistry, Tina ^a,b   Digby, Janet E ^a   Desai, Ken M ^b   Randeva, Harpal S ^a  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

Author keywords

Adipokines; Adiponectin; Interleukin 6; Leptin; Obesity; Prostate cancer; Vascular endothelial growth factor

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; INTERLEUKIN 6; LEPTIN; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; CANCER CELL; CANCER GRADING; CANCER INVASION; CANCER RISK; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOKINE PRODUCTION; HUMAN; OBESITY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

ADIPOCYTES; ADIPONECTIN; APOPTOSIS; CELL DIFFERENTIATION; CELL PROLIFERATION; DISEASE PROGRESSION; HUMANS; MALE; OBESITY; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 34249018265     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2007.03.054     Document Type: Review

References (50)

1. Aus G., Abbou C.C., Bolla M., et al. EAU guidelines on prostate cancer. Eur Urol 48 (2005) 546-551
2. Vercelli M., Quaglia A., Marani E., and Parodi S. Prostate cancer incidence and mortality trends among elderly and adult Europeans. Crit Rev Oncol Hematol 35 (2000) 133-144
3. Pu Y.S., Chiang H.S., Lin C.C., Huang C.Y., Huang K.H., and Chen J. Changing trends of prostate cancer in Asia. Aging Male 7 (2004) 120-132
4. Kershaw E.E., and Flier J.S. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89 (2004) 2548-2556
5. Freedland S.J., Giovannucci E., and Platz E.A. Are findings from studies of obesity and prostate cancer really in conflict?. Cancer Causes Control 17 (2006) 5-9
6. von Hafe P., Pina F., PerezA, Tavares M., and Barros H. Visceral fat accumulation as a risk factor for prostate cancer. Obes Res 12 (2004) 1930-1935
7. Pasquali R., Casimirri F., De Iasio R., et al. Insulin regulates testosterone and sex hormone-binding globulin concentrations in adult normal weight and obese men. J Clin Endocrinol Metab 80 (1995) 654-658
8. Massengill J.C., Sun L., Moul J.W., et al. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol 169 (2003) 1670-1675
9. Schatzl G., Madersbacher S., Thurridl T., et al. High-grade prostate cancer is associated with low serum testosterone levels. Prostate 47 (2001) 52-58
10. Freedland S.J. Obesity and prostate cancer: a growing problem. Clin Cancer Res 11 (2005) 6763-6766
11. Gann P.H., Hennekens C.H., Sacks F.M., Grodstein F., Giovannucci E.L., and Stampfer M.J. Prospective study of plasma fatty acids and risk of prostate cancer. J Natl Cancer Inst 86 (1994) 281-286
12. Le Marchand L., Kolonel L.N., Wilkens L.R., Myers B.C., and Hirohata T. Animal fat consumption and prostate cancer: a prospective study in Hawaii. Epidemiology 5 (1994) 276-282
13. Brown M.D., Hart C.A., Gazi E., Bagley S., and Clarke N.W. Promotion of prostatic metastatic migration towards human bone marrow stoma by omega 6 and its inhibition by omega 3 PUFAs. Br J Cancer 94 (2006) 842-853
14. Pandalai P.K., Pilat M.J., Yamazaki K., Naik H., and Pienta K.J. The effects of omega-3 and omega-6 fatty acids on in vitro prostate cancer growth. Anticancer Res 16 (1996) 815-820
15. Wang Y., Corr J.G., Thaler H.T., Tao Y., Fair W.R., and Heston W.D. Decreased growth of established human prostate LNCaP tumors in nude mice fed a low-fat diet. J Natl Cancer Inst 87 (1995) 1456-1462
16. Platz E.A., Leitzmann M.F., Visvanathan K., et al. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 98 (2006) 1819-1825
17. Tokuda Y., Satoh Y., Fujiyama C., Toda S., Sugihara H., and Masaki Z. Prostate cancer cell growth is modulated by adipocyte-cancer cell interaction. BJU Int 91 (2003) 716-720
18. Onuma M., Bub J.D., Rummel T.L., and Iwamoto Y. Prostate cancer cell-adipocyte interaction: leptin mediates androgen-independent prostate cancer cell proliferation through c-Jun NH2-terminal kinase. J Biol Chem 278 (2003) 42660-42667
19. Zhang Y., Proenca R., Maffei M., Barone M., Leopold L., and Friedman J.M. Positional cloning of the mouse obese gene and its human homologue. Nature 372 (1994) 425-432
20. Considine R.V., Sinha M.K., Heiman M.L., et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 334 (1996) 292-295
21. Nazian S.J., and Cameron D.F. Temporal relation between leptin and various indices of sexual maturation in the male rat. J Androl 20 (1999) 487-491
22. Chang S., Hursting S.D., Contois J.H., et al. Leptin and prostate cancer. Prostate 46 (2001) 62-67
23. Stattin P., Soderberg S., Hallmans G., et al. Leptin is associated with increased prostate cancer risk: a nested case-referent study. J Clin Endocrinol Metab 86 (2001) 1341-1345
24. Hsing A.W., Chua Jr. S., Gao Y.T., et al. Prostate cancer risk and serum levels of insulin and leptin: a population-based study. J Natl Cancer Inst 93 (2001) 783-789
25. Saglam K., Aydur E., Yilmaz M., and Goktas S. Leptin influences cellular differentiation and progression in prostate cancer. J Urol 169 (2003) 1308-1311
26. Somasundar P., Frankenberry K.A., Skinner H., et al. Prostate cancer cell proliferation is influenced by leptin. J Surg Res 118 (2004) 71-82
27. Miyazaki T., Bub J.D., Uzuki M., and Iwamoto Y. Adiponectin activates c-Jun NH2-terminal kinase and inhibits signal transducer and activator of transcription 3. Biochem Biophys Res Commun 333 (2005) 79-87
28. Fain J.N., Madan A.K., Hiler M.L., Cheema P., and Bahouth S.W. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 145 (2004) 2273-2282
29. Culig Z., Steiner H., G. Bartsch G., and Hobisch A. Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem 95 (2005) 497-505
30. Nakashima J., Tachibana M., Horiguchi Y., et al. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 6 (2000) 2702-2706
31. Giri D., Ozen M., and Ittmann M. Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol 159 (2001) 2159-2165
32. Chung T.D., Yu J.J., Spiotto M.T., Bartkowski M., and Simons J.W. Characterization of the role of IL-6 in the progression of prostate cancer. Prostate 38 (1999) 199-207
33. Hobisch A., Ramoner R., Fuchs D., et al. Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype. Clin Cancer Res 7 (2001) 2941-2948
34. Miyazawa-Hoshimoto S., Takahashi K., Bujo H., Hashimoto N., and Saito Y. Elevated serum vascular endothelial growth factor is associated with visceral fat accumulation in human obese subjects. Diabetologia 46 (2003) 1483-1488
35. Frankenberry K.A., Somasundar P., McFadden D.W., and Vona-Davis L.C. Leptin induces cell migration and the expression of growth factors in human prostate cancer cells. Am J Surg 188 (2004) 560-565
36. Steiner H., Berger A.P., Godoy-Tundidor S., et al. An autocrine loop for vascular endothelial growth factor is established in prostate cancer cells generated after prolonged treatment with interleukin 6. Eur J Cancer 40 (2004) 1066-1072
37. Duque J.L., Loughlin K.R., Adam R.M., Kantoff P.W., Zurakowski D., and Freeman M.R. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 54 (1999) 523-527
38. Kuniyasu H., Troncoso P., Johnston D., et al. Relative expression of type IV collagenase, E-cadherin, and vascular endothelial growth factor/vascular permeability factor in prostatectomy specimens distinguishes organ-confined from pathologically advanced prostate cancers. Clin Cancer Res 6 (2000) 2295-2308
39. Baillargeon J., and Rose D.P. Obesity, adipokines, and prostate cancer (review). Int J Oncol 28 (2006) 737-745
40. Kadowaki T., and Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 26 (2005) 439-451
41. Kelesidis I., Kelesidis T., and Mantzoros C.S. Adiponectin and cancer: a systematic review. Br J Cancer 94 (2006) 1221-1225
42. Goktas S., Yilmaz M.I., Caglar K., Sonmez A., Kilic S., and Bedir S. Prostate cancer and adiponectin. Urology 65 (2005) 1168-1172
43. Luo X.H., Guo L.J., Yuan L.Q., et al. Adiponectin stimulates human osteoblasts proliferation and differentiation via the MAPK signaling pathway. Exp Cell Res 309 (2005) 99-109
44. Levy D.E., and Darnell Jr. J.E. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 3 (2002) 651-662
45. Davis R.J. Signal transduction by the JNK group of MAP kinases. Cell 103 (2000) 239-252
46. Mistry T., Digby J.E., Chen J., Desai K.M., and Randeva H.S. The regulation of adiponectin receptors in human prostate cancer cell lines. Biochem Biophys Res Commun 348 (2006) 832-838
47. Bub J.D., Miyazaki T., and Iwamoto Y. Adiponectin as a growth inhibitor in prostate cancer cells. Biochem Biophys Res Commun 340 (2006) 1158-1166
48. Chen D.C., Chung Y.F., Yeh Y.T., et al. Serum adiponectin and leptin levels in Taiwanese breast cancer patients. Cancer Lett 237 (2006) 109-114
49. Nilsen T.I., Romundstad P.R., and Vatten L.J. Recreational physical activity and risk of prostate cancer: a prospective population-based study in Norway (the HUNT study). Int J Cancer 119 (2006) 2943-2947
50. Diez J.J., and Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 148 (2003) 293-300